Non-Small Cell Lung Cancer - Immunotherapy

November 8, 2015

Learning Objectives

  • Discuss basic science behind the human immune response
  • Describe how the checkpoint inhibitors alter the body’s immune response to Non-small cell lung cancer cells
  • Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis
  • Explain how checkpoint inhibitors differ from other available treatment options for metastatic NSCLC, including kinase inhibitors and cytotoxic chemotherapy
  • Identify FDA approved checkpoint inhibitors and their indications, including relevant aspects of patient selection
Course summary
Available credit: 
  • 0.75 AANP
  • 0.75 Pharmacology
  • 0.75 ACPE
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Attendance
  • 0.75 ANCC
Course opens: 
11/08/2015
Course expires: 
02/29/2016
Event starts: 
11/08/2015 - 8:00am
Event ends: 
11/08/2015 - 8:45am
Cost:
$0.00
Rating: 
0
United States

Suzanne Walker, CRNP, MSN, AOCN, BC
Sukmani Padda, MD

Available Credit

  • 0.75 AANP
  • 0.75 Pharmacology
  • 0.75 ACPE
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Attendance
  • 0.75 ANCC

Price

Cost:
$0.00
Please login or register to take this course.